We are transforming the treatment of diabetic foot disease by curing from within.
Triovance was founded to develop innovative treatments for diabetes, inspired by the founders' personal loss of their fathers to the disease. The company began in Mexico, focusing on gene and cell therapies, and in 2019 secured funding from Jaime Cervantes, president of the Vitalmex Group, to tackle diabetic foot ulcers. After five years of research, Triovance developed a breakthrough skin substitute designed to be safe, affordable, and accessible for low-income patients.
In 2023, Triovance received FDA feedback during its first pre-IND meeting, leading to the formation of Triovance Holding LLC in San Diego, CA.
With an experienced manufacturing team and support from Azzur Cleanrooms on Demand, the company scaled production under Good Manufacturing Practices (GMP). Triovance is driven by an experienced team, expert advisors and key partners, who are all committed to expanding operations and delivering life-changing solutions for patients in need.
Our mission is to improve the quality of life of patients with chronic-degenerative diseases such as diabetes with innovative products based on tissue engineering, gene therapy and cell therapy.
Meet the team behind Triovance
Executive Team
Our mission is to improve the quality of life of patients with chronic-degenerative diseases such as diabetes with products based ontissue engineering, gene therapy, and cell therapy.
Blanca Segura, PhD
Blanca is a 20+ year cell and gene therapy expert and seasoned inventor of innovative research methods and medical devices, including co-development of an epigenetic drug and co-invention of two medical devices for diabetes. As founder and CEO of Triovance, she leads the company in advancing a portfolio of products that address type 2 diabetes and its complications. Previously, she served as CSO at Global BioTherapeutics and PI and researcher at the National Cancer Institute, Mexico.
Ian Wisenberg
Ian Wisenberg is an international business executive with more than 35 years of experience spanning corporate development, finance, and strategic partnerships. He has played a significant role in helping life sciences and healthcare companies’ access and expand across global markets in the United States, Europe, and Asia. He currently serves as Chairman and CEO of Triovance, Managing Director of BioGlobal Consulting Group, and Director of Clever Culture Systems. In these roles, he focuses on strategic growth, financing, cross-border business development, and the formation of high-value partnerships.Previously, Ian served as CEO, Co-founder, and Executive Chairman of BioCina, and as CFO of BioDuro. Over the course of his career, he has built a strong reputation for aligning capital, commercial strategy, and international relationships to support company growth and value creation.
Clinical & Scientific Advisors
%203.33.33%E2%80%AFp.m..png)
Professor of Surgery at the USC. Dr. Armstrong holds a M of Sc in Tissue Repair and Wound Healing from the U of Wales and a PhD from the U of Manchester. Has produced more than 595 peer-reviewed. Was selected as one of the first six International Wound Care Ambassadors. Founder and co-chair of the International Diabetic Foot Conference. Founding President of the American Limb Preservation Society (ALPS)
30+ years commercial experience in life sciences, focusing on cell & gene therapy. Co-founder of numerous companies, Senior VP of R&D at New York Stem Cell Fdn, Co-author of 30+ published papers, inventor on 50+ patents worldwide, and has filed over 15 INDs at the FDA.
Dr. Dennis Kim, President and CEO of Xeno Biosciences, is an endocrinologist and specializes inmetabolic diseases. He has held senior roles at CymaBay, Orexigen, and Amylin Pharmaceuticals, where he led the development of Byetta® for type 2 diabetes.
Dan Maneval is a scientific leader with extensive biotech and biopharma experience, contributing to all stages of drug development, including Herceptin®, Adstiladrin®, HYQVIA™, and HYLECTA™.
He is the recipient of the 21st Annual JohnBoswick Award for lifelong achievement in the field of wound care.Program Director, Vascular and Wound Care Center New JerseyMedical School. He is also a Voluntary Associate Professor, PhillipFrost Department of Dermatology and Cutaneous Surgery
